Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Among lecanemab recipients, 17% had brain bleeding, compared with 9% in the placebo group, and 13% had brain swelling, compared with 2% given a placebo.

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

Lecanemab and other drugs that remove amyloid have another side effect that is more mysterious: They seem to cause the brain to shrink. That concerns scientists including Thambisetty.

Lecanemab, an Alzheimer's drug from Eisai and Biogen, was found to slow the cognitive decline among people with early signs of the disease.

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...